loading
전일 마감가:
$17.92
열려 있는:
$17.87
하루 거래량:
2.73M
Relative Volume:
1.99
시가총액:
$1.76B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-38.02
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
-0.28%
1개월 성능:
+3.53%
6개월 성능:
+26.92%
1년 성능:
+59.70%
1일 변동 폭
Value
$17.41
$18.05
1주일 범위
Value
$17.41
$18.17
52주 변동 폭
Value
$8.9055
$18.90

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
명칭
Ars Pharmaceuticals Inc
Name
전화
858-771-9307
Name
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
직원
160
Name
트위터
Name
다음 수익 날짜
2024-12-13
Name
최신 SEC 제출 서류
Name
SPRY's Discussions on Twitter

SPRY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
17.87 1.76B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-07 개시 Scotiabank Sector Outperform
2025-02-10 개시 Oppenheimer Outperform
2024-08-20 개시 Cantor Fitzgerald Overweight
2024-08-13 업그레이드 Raymond James Outperform → Strong Buy
2024-08-12 재확인 Leerink Partners Outperform
2024-07-25 개시 Raymond James Outperform
2024-03-05 업그레이드 Leerink Partners Market Perform → Outperform
2024-02-20 업그레이드 William Blair Mkt Perform → Outperform
2023-09-20 다운그레이드 William Blair Outperform → Mkt Perform
2023-01-31 개시 Wedbush Outperform
2023-01-03 개시 William Blair Outperform
2022-12-13 개시 SVB Leerink Outperform
모두보기

Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스

pulisher
07:52 AM

When is ARS Pharmaceuticals Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - jammulinksnews.com

07:52 AM
pulisher
04:30 AM

Should I hold or sell ARS Pharmaceuticals Inc. stock in 2025Consistent double returns - jammulinksnews.com

04:30 AM
pulisher
Jul 25, 2025

ARS Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

What drives ARS Pharmaceuticals Inc. stock priceTremendous growth opportunities - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about ARS Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Yahoo Finance

Jul 18, 2025
pulisher
Jul 15, 2025

ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance

Jul 15, 2025
pulisher
Jul 10, 2025

ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 09, 2025

(SPRY) Technical Data - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 09, 2025

ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 03, 2025

ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest

Jul 03, 2025
pulisher
Jul 01, 2025

ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Raymond James reiterates strong buy on ARS Pharmaceuticals stock - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

ARS Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 26, 2025
pulisher
Jun 23, 2025

High Growth Tech Stocks in US for June 2025 - simplywall.st

Jun 23, 2025
pulisher
Jun 21, 2025

Ars pharma CCO Karas sells $240k in SPRY stock - Investing.com India

Jun 21, 2025
pulisher
Jun 18, 2025

Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

ARS Pharmaceuticals | 6/18/25 - ktnv.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living

Jun 18, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com

Jun 17, 2025
pulisher
Jun 15, 2025

ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey

Jun 15, 2025

Ars Pharmaceuticals Inc (SPRY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Ars Pharmaceuticals Inc 주식 (SPRY) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Karas Eric
Chief Commercial Officer
Jul 01 '25
Sale
16.99
15,000
254,860
10,315
Flynn James E
10% Owner
Jun 27 '25
Sale
18.46
740,149
13,663,151
4,887,254
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):